health_and_safetyGLP-1 Q&A

Who Should NOT Take a GLP-1

There are hard contraindications and there are soft cautions. Here's the difference, lifted from the actual FDA labels for Wegovy, Ozempic, Zepbound, and Mounjaro.

The short answer

GLP-1 medications are contraindicated in three groups absolutely: people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2), people with a known serious hypersensitivity to the drug, and people who are pregnant (for weight-management indications). Several other conditions — severe gastroparesis, recent pancreatitis, severe GERD, type 1 diabetes without specialist input — are not absolute contraindications but make most prescribers either steer away or proceed with significant caution.

What the research says

The hard contraindications come straight from the FDA labels. The Wegovy and Zepbound labels both list two absolute contraindications: personal or family history of MTC or MEN-2, and prior serious hypersensitivity to the active ingredient or excipients. The thyroid contraindication is based on rodent studies showing dose-dependent C-cell tumors at clinically relevant exposures; the hypersensitivity contraindication is based on post-marketing reports of anaphylaxis and angioedema.

Pregnancy is treated separately on the labels. For weight-management indications, the label directs prescribers to discontinue the drug upon recognition of pregnancy, with a 2-month washout before planned conception because of the roughly one-week half-life. Breastfeeding is also not recommended; injectable forms lack human milk data, and the oral form (Rybelsus) contains an absorption enhancer that has been detected in milk.

Beyond the absolute contraindications, the labels carry warnings and precautions that often shape prescribing in practice. Pancreatitis: every GLP-1 label warns about acute pancreatitis and recommends discontinuation if it occurs. People with a prior episode of pancreatitis are not absolutely barred, but most prescribers will steer to a different therapy or proceed with very close monitoring. Gallbladder disease: the labels note an increased risk of cholelithiasis and acute gallbladder disease, particularly with rapid weight loss. Acute kidney injury can occur secondary to dehydration from GI side effects, which puts patients with significant chronic kidney disease in a higher-risk category. Diabetic retinopathy: the Ozempic and Wegovy labels carry a specific warning about rapid improvement in glycemic control sometimes worsening pre-existing diabetic retinopathy.

Severe gastroparesis is a particularly nuanced exclusion. GLP-1s work in part by slowing gastric emptying. People who already have severe gastroparesis can experience worsening symptoms — persistent vomiting, bezoars, severe early satiety. It is not on every label as a contraindication, but it is on most prescribers' practical exclusion list.

Type 1 diabetes is not an absolute contraindication for the GLP-1 class, but the drugs are not FDA-approved for that indication, and prescribing requires endocrinology input because of hypoglycemia and DKA considerations. Children and adolescents are a separate question: Wegovy is FDA-approved down to age 12 with specific criteria; tirzepatide is not currently approved in pediatric populations.

What this means for you

If any of the absolute contraindications apply to you, the conversation stops there. MTC/MEN-2 history (yours or a first-degree relative's) means no GLP-1, period. A documented serious hypersensitivity to a prior GLP-1 means no further attempts at the class.

If you have a history of pancreatitis, gallbladder disease, severe GI motility issues, advanced kidney disease, or proliferative diabetic retinopathy, that does not necessarily mean no GLP-1 — but it does mean the conversation should be careful, specific, and probably involve more than just a primary-care prescription. Many of these conditions are managed with monitoring rather than avoidance.

If you are pregnant or trying to conceive within the next 2 months, postpone starting therapy until the conception question is resolved. The washout window for semaglutide and tirzepatide is set at 2 months before planned conception in the labels.

If you fit none of the contraindications but still feel uncertain, a structured visit with a prescriber who knows your full history — not just your weight — is the right next step. The label exclusions are narrow; most adults with obesity-related health risk are candidates.

Key takeaways

block

MTC, MEN-2, and pregnancy are hard stops

Personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, or current pregnancy means no GLP-1. These are absolute contraindications on every label.

warning

Pancreatitis and gastroparesis are soft stops

These are not blanket contraindications but make most prescribers steer to a different therapy or proceed with close monitoring rather than start routinely.

fact_check

Most adults are still candidates

Label exclusions are narrow. If none of the absolute contraindications apply, a structured prescribing visit is the right next step — not blanket disqualification.

Common questions

Common Concerns

Can I take a GLP-1 if I had pancreatitis 10 years ago?expand_more

A remote single episode of pancreatitis is not an absolute contraindication, but it is a significant warning. Most prescribers will discuss the trade-offs carefully and either choose a different therapy or proceed with closer monitoring (symptom education, possible baseline lipase). A history of recurrent pancreatitis is generally a hard exclusion.

What if my aunt had medullary thyroid cancer?expand_more

MTC contraindication on the GLP-1 label is typically interpreted as first-degree relatives (parents, siblings, children). An aunt is a second-degree relative, which most prescribers do not treat as a hard contraindication — but they will likely want a more detailed family history and may recommend genetic counseling if MEN-2 has not been ruled out in your family.

I have severe GERD. Can I still take a GLP-1?expand_more

Severe GERD is not a labeled contraindication, but GLP-1s can worsen reflux because of delayed gastric emptying. Many people with mild-to-moderate GERD do fine; people with severe or refractory GERD may find symptoms worsen. This is a conversation to have with your prescriber and your GI specialist if you have one.

Can I take a GLP-1 with kidney disease?expand_more

Mild to moderate chronic kidney disease is not a contraindication. The label warning is about acute kidney injury secondary to dehydration from GI side effects — meaning prevention of nausea/vomiting/diarrhea-driven dehydration is the practical priority. People with severe CKD or on dialysis need specialist input.

What about people on insulin or sulfonylureas?expand_more

Combining a GLP-1 with insulin or a sulfonylurea increases the risk of hypoglycemia. This is not a contraindication, but it usually means the prescriber will reduce the insulin or sulfonylurea dose when starting the GLP-1, and monitor blood sugar more closely during titration.

Keep exploring

Browse all GLP-1 guides.